SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Gilead Science (GILD) Followers
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
961 87 0 GILD
Emcee:  SybilNicolas Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
786Merrill's take USPTO Viread patent ruling incremental positive The USPTO cotom pope-5/21/2008
785U.S. Patent Office Confirms First of Four Viread(R) Patents Tuesday May 20, 5:05tnsaf-5/20/2008
784Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patienttnsaf-5/20/2008
783European Commission Approves Viread(R) for Chronic Hepatitis B Friday April 25, tnsaf-4/25/2008
782Gilead announces 72-week data from two Ph. III studies evaluating Viread for tretnsaf-4/24/2008
781Merrill Price Objective Change Gilead Sciences Inc (GILD, US$49.61, C-1-9) Raistom pope-3/25/2008
780Europe’s CHMP Approves Viread for HBV: siliconinvestor.comDewDiligence_on_SI-3/19/2008
779Gilead Sciences Swings to a 4th-Quarter Profit From Year-Ago Quarter Weighed by tnsaf-1/23/2008
778You might enjoy exploring this thread: Subject 53258 Good luck! BobThe Dodgy Ticker-1/14/2008
777Thanks for the reply. I'll poke around for it. I'm into momentum/swinggoldenrodger-1/12/2008
776Not really wilderness. Discussion at S.I. with biotechs tends to focus on smallscaram(o)uche-1/11/2008
775Maybe posting in the wilderness here but If you look at the current GILD formatigoldenrodger-1/10/2008
774Gilead submits cystic fibrosis treatment application to FDA By MarketWatch - Latnsaf-11/17/2007
773Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viretnsaf-11/2/2007
772Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patientstnsaf-10/23/2007
771Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Putnsaf-9/24/2007
770Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates foscaram(o)uche-8/15/2007
769Gilead Sciences Announces Second Quarter 2007 Financial Results Thursday July 19tnsaf-7/19/2007
768Gilead's War on AIDS By JAY PALMER MONDAY, JULY 9, 2007 HEART DISEASE, CADoc Bones-7/7/2007
767U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentakenhott-6/15/2007
766From Merrill's Morning Call Company Updates Gilead Sciences Inc (GILD, US$7tom pope-3/27/2007
765Merrill: Upgrade to BUY; Target of $91: We are upgrading GILD to BUY from NEUTtom pope-3/20/2007
764I was just rattling your cage, Tuck :-)tom pope-1/31/2007
763I typed that before the conference call, Tom, and then it was only up 50 cents otuck-1/31/2007
762<i>Gilead is up a bit after hours.</i> Man, you're hard to pleatom pope-1/31/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News